Heinz-Josef Lenz
Colorectal oncologist who led CheckMate 142 and co-led CheckMate 8HW, bringing nivolumab plus ipilimumab to MSI-high disease.
Overview
Heinz-Josef Lenz was a lead investigator of CheckMate 142 and CheckMate 8HW, which established nivolumab plus ipilimumab in MSI-high colorectal cancer, and led the analyses of CALGB/SWOG 80405 showing that primary tumour side predicts benefit from anti-EGFR therapy. He has long studied pharmacogenomics of fluoropyrimidines and leads SWOG GI trials.
| Title | Journal | Year |
|---|---|---|
| First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study | JCO | 2022 |
| Impact of primary (1º) tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance) | JCO | 2016 |
Pages like this
not linked directly; found by shared links- PersonThierry André
Shares CheckMate 8HW, CTLA-4, Ipilimumab, Nivolumab and the tags colorectal, immunotherapy.
- PersonPaul Baas
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.
- PersonMichael A. Postow
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.
- PersonJedd D. Wolchok
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.
- TrialCheckMate 9DW
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
- TrialCheckMate 648
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
- PersonCaroline Robert
Shares Ipilimumab, Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonTina Cascone
Shares Ipilimumab, Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.